IN FOCUS Study
Assessing Chemotherapy Induced Peripheral Neuropathy
What is Chemotherapy induced peripheral neuropathy (CIPN)?
CIPN occurs when certain types of chemotherapy damage peripheral nerves. This can result in numbness, tingling, pain or weakness in the feet, lower legs, hands and fingers.
What is the purpose of this study?
The purpose of this research project is to improve our understanding of nerve problems following chemotherapy treatment in people with cancer, which may lead to better treatment and management of these symptoms.
What does the study involve?
You will be asked to undertake several tests to investigate your hand function. These will include tests to assess the sensitivity of your sense of touch and tests to examine your manual dexterity and how quickly you can manipulate objects.
You will be asked to undergo a non- invasive nerve conduction study or excitability study of the nerves supplying the hand and feet. These tests record the properties of electrical impulses travelling along your nerves using stick-on-electrodes.
Medical history and Examination
We will ask you about your medical history, current medications and any risk factors for nerve damage. Then a brief standard neurological clinical examination will be undertaken to assess your nerve function.
You will be asked to complete questions relating to nerve symptoms, how they effect your daily life. Some questions will enquire as to your use of health services, income and work status to try to determine the overall impacts of nerve damage.
How long will it take?
The assessments will take around 1.5 - 2 hours. If you are about to begin your chemotherapy, we would like to conduct these assessments before you start your treatment, midway, at the end of treatment and at a follow-up appointment. If you have already completed your chemotherapy, there would only be one assessment Confidentiality Any information obtained in connection with this research project that can identify you will remain confidential.
Further information can be provided by the Participant information Statement and Consent Form. This contains additional, pertinent information and should be read prior to agreeing to take part. For a copy or any other enquiries about the study contact:
Dr Eva Battaglini
T: 02 9382 8837
T: 02 9382 2413